Emerging intravesical therapies for management of nonmuscle invasive bladder cancer

Transitional cell carcinoma (TCC) is the second most common urologic malignancy, and 70% of patients present with superficial or nonmuscle invasive bladder cancer (NMIBC). Intravesical bacillus Calmette-Guerin (BCG) is the most effective agent for preventing disease recurrence, and the only therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomaszewski, Jeffrey J, Smaldone, Marc C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818881/
https://www.ncbi.nlm.nih.gov/pubmed/24198616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818881/
https://www.ncbi.nlm.nih.gov/pubmed/24198616

Ejemplares similares